OrbiMed’s Dianthus Therapeutics DNTH Stock Holding History

OrbiMed’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.2M	Buy	+115,000	New	+$10M	0.21%	82
2022 Q4	–	Sell	-140,685	Closed	-$3.17M	–	119
2022 Q3	$3.17M	Hold	140,685	–	–	0.06%	114
2022 Q2	$2.7M	Hold	140,685	–	–	0.05%	124
2022 Q1	$6.53M	Hold	140,685	–	–	0.11%	112
2021 Q4	$9.97M	Buy	140,685 +22,375	+19%	+$2.25M	0.13%	115
2021 Q3	$13.8M	Sell	118,310 -8,800	-7%	-$1.03M	0.15%	114
2021 Q2	$19.9M	Buy	127,110 +67,794	+114%	+$12.5M	0.2%	99
2021 Q1	$11.2M	Buy	+59,316	New	+$9.98M	0.11%	118

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

OrbiMed's DNTH Position: Q2 2026 in Review

OrbiMed opened a new position in Dianthus Therapeutics (DNTH) in Q2 2026: 115,000 shares worth $11.2M. The stake represents 0.21% of the portfolio and ranks #82 among its holdings. This is a return to the name: OrbiMed previously reported a position in DNTH as recently as Q3 2022.

OrbiMed first reported a position in DNTH in Q1 2021 and has held it in 8 quarters since. The position peaked at $19.9M in Q2 2021. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

OrbiMed held 115,000 shares of Dianthus Therapeutics worth $11.2M as of Q2 2026.
Dianthus Therapeutics was a new OrbiMed position in Q2 2026.
Dianthus Therapeutics made up 0.21% of OrbiMed's portfolio in Q2 2026, its #82 holding.
OrbiMed first reported a position in Dianthus Therapeutics in Q1 2021 and has held it in 8 quarters since.
OrbiMed's Dianthus Therapeutics position peaked at $19.9M in Q2 2021.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.